Expert: “the bar should be high” before you grant a drug patent “monopoly”

This week, the Indian Supreme Court annulled a patent for a leukemia drug created by Swiss pharmaceutical company Novartis, opening the door for generic versions.

Due Diligence’s Carmen Russell-Sluchansky talks with Swaminathan S. Anklesaria Aiyar, Indian Economist and Fellow at the Cato Institute:



Aiyar counters challenges that the Indian Supreme Court is “anti-patent”, saying that, instead, India has very high standards for granting a patent. Rather than, for example, a salt change in the drug, patents are instead only given for things which improve the efficiency of drug because, in the Indian view, “to grant a patent is to grant a monopoly.”

About Carmen Munir Russell-Sluchansky 360 Articles
Carmen is a multimedia journalist based in Washington, DC whose work has appeared in a variety of outlets including National Geographic, NBC News, the BBC, Asia! Magazine, The China Post, Chicago Tribune and Orlando Sentinel.